Posts

Showing posts with the label pioglitazone

pioglitazone and risk of bladder cancer

There have been conflicting reports about piogitazone and bladder cancer over the years. T he FDA just came out with a specific updated review and warning (see http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm532772.htm for the brief statement and http://www.fda.gov/Drugs/DrugSafety/ucm519616.htm for the document). In 2010 the FDA commented that there was the potential for bladder cancer based on some human and animal studies, but they did not conclude there was an increased risk, the review was ongoing, and that patients should not stop taking pioglitazone. In 2011 they did require the manufacturer to include the bladder cancer warning. --the updated 2016 warning: --pioglitazone should not be given to those with active bladder cancer --clinicians should “carefully consider the benefits and risks before using pioglitazone in patients with a history of bladder cancer" --patients should contact their clinician if they ...

diabetes update AHRQ, and pioglitazone to prevent cardiovasc disease

the Agency for Healthcare Research and Quality (AHRQ)  just published an update on diabetes meds for adults with type 2 DM, looking at some of the newer studies on the meds (see  https://www.effectivehealthcare.ahrq.gov/ehc/products/607/2215/diabetes-update-2016-report.pdf ​ , also published in annals of internal medicine at  doi:10.7326/M15-2650  ).  they assessed 4 key questions (KQs). findings (which limited in many cases by lack of reasonable studies): KQ 1. comparative effectiveness of monotherapies for A1c, weight, systolic BP (SBP), and heart rate; and in particular for metformin-based combinations --for reducing A1c:     --metformin, thiazolidinediones (TZDs) and sulfonylureas (SU) were best. DPP-4 inhibitors less good     --combos of metformin plus TZD, SU, SGLT-2 inhibitors and DPP-4 inhibitors were generally better in lowering A1c than metformin alone. (best were metformi...